Swiss generics and biosimilars giant Sandoz (SIX: SDZ) today announced financial results for the full year 2024, showing that sales were$10.4 billion, up by 9% in constant currencies (+7% in $). Fourth-quarter net sales of $2.7 billion, up by 9% in constant currencies (+7% in $).
The majority of revenues came for generics, which came in at $7,504 million (+1% YoY, +2% CER), with biosimilars sales of $2,853(+29% YoY, +30% CER). Strong sales performances in all three regions, was driven by double-digit growth in biosimilars, both in the fourth quarter and full year, benefitting from recent launches and base-business momentum
Operating income of $307 million, was up by 5% in constant currencies (-18% in $). Core earnings before interest, tax, depreciation and amortization (EBITDA) were $2.08 billion, up 24% (+19 in $).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze